Vertex Pharma (VRTX) Posts Smaller Q4 Loss

Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of ($0.55), $0.10 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $145 million versus the consensus estimate of $137.5 million.

"The potential approval and launch of the combination of lumacaftor and ivacaftor and continued label and geographic expansion for KALYDECO are expected to significantly increase both the number of people treated with our medicines and our revenues to support the long-term growth of our business," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "As our revenues grow over the coming years, we remain committed to both controlling our operating expenses to generate significant earnings growth and to investing in research and development to create transformative new medicines."

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Ledyard Financial Group adds two directors, three retire
• Super Micro Computer rises on AI server market optimism